{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:29:49Z","timestamp":1788449389326,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10072-025-08096-9","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:40:10Z","timestamp":1743075610000},"page":"3271-3279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3791","authenticated-orcid":false,"given":"Rita","family":"Frangiamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-7238","authenticated-orcid":false,"given":"Elena","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-6462","authenticated-orcid":false,"given":"Fiammetta","family":"Vanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-8830","authenticated-orcid":false,"given":"Francesca","family":"Andreetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora Giacopuzzi","family":"Grigoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-123X","authenticated-orcid":false,"given":"Emilio","family":"Ciusani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-6821","authenticated-orcid":false,"given":"Silvia","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-5173","authenticated-orcid":false,"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"12","key":"8096_CR1","doi-asserted-by":"publisher","first-page":"e179742","DOI":"10.1172\/JCI179742","volume":"134","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL (2024) Myasthenia Gravis: the future is here. J Clin Invest 134(12):e179742. https:\/\/doi.org\/10.1172\/JCI179742","journal-title":"J Clin Invest"},{"key":"8096_CR2","doi-asserted-by":"publisher","first-page":"1404191","DOI":"10.3389\/fimmu.2024.1404191","volume":"15","author":"P Cavalcante","year":"2024","unstructured":"Cavalcante P, Mantegazza R, Antozzi C (2024) Targeting autoimmune mechanisms by precision medicine in myasthenia Gravis. Front Immunol 15:1404191. https:\/\/doi.org\/10.3389\/fimmu.2024.1404191","journal-title":"Front Immunol"},{"issue":"6","key":"8096_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, Bril V (2024) FcRn inhibitor therapies in neurologic diseases. CNS Drugs 38(6):425\u2013441. https:\/\/doi.org\/10.1007\/s40263-024-01090-3","journal-title":"CNS Drugs"},{"key":"8096_CR4","doi-asserted-by":"publisher","unstructured":"Heo Y-A (2022) Efgartigimod: first approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","DOI":"10.1007\/s40265-022-01678-3"},{"issue":"14","key":"8096_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM, Rozanolixizumab (2023) First Approval Drugs 83(14):1341\u20131347. https:\/\/doi.org\/10.1007\/s40265-023-01933-1","journal-title":"First Approval Drugs"},{"key":"8096_CR6","doi-asserted-by":"publisher","first-page":"e200038","DOI":"10.1212\/NXI.0000000000200038","volume":"10","author":"G Spagni","year":"2023","unstructured":"Spagni G, Gastaldi M, Businaro P et al (2023) Comparison of fixed and live cell-based assay for the detection of achr and musk antibodies in myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 10:e200038. https:\/\/doi.org\/10.1212\/NXI.0000000000200038","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"8096_CR7","doi-asserted-by":"publisher","first-page":"e16306","DOI":"10.1111\/ene.16306","volume":"31","author":"B Sorrenti","year":"2024","unstructured":"Sorrenti B, Laurini C, Bosco L et al (2024) Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia Gravis patient with Efgartigimod. Eur J Neurol 31(7):e16306. https:\/\/doi.org\/10.1111\/ene.16306","journal-title":"Eur J Neurol"},{"issue":"4","key":"8096_CR8","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F et al (2024) Efgartigimod in generalized myasthenia Gravis: A real-life experience at a National reference center. Eur J Neurol 31(4):e16189. https:\/\/doi.org\/10.1111\/ene.16189","journal-title":"Eur J Neurol"},{"key":"8096_CR9","doi-asserted-by":"crossref","unstructured":"Jaretzki A 3rd 1, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 12;55;16\u201323","DOI":"10.1212\/WNL.55.1.16"},{"key":"8096_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia Gravis clinical research and care. Muscle Nerve 65:630\u2013639","journal-title":"Muscle Nerve"},{"key":"8096_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB (2010) The MG composite. A valid and reliable measure for myasthenia Gravis. Neurology 74:1434\u20131440","journal-title":"Neurology"},{"key":"8096_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1212\/01.WNL.0000163988.28892.79","volume":"64","author":"RS Bedlack","year":"2005","unstructured":"Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia Gravis: assessment of responsiveness and longitudinal validity. Neurology 64:196","journal-title":"Neurology"},{"key":"8096_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia Gravis activities of daily living profile. Neurology 52:1487\u20131489","journal-title":"Neurology"},{"key":"8096_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia Gravis score. Ann N Y Acad Sci 841:769\u2013772","journal-title":"Ann N Y Acad Sci"},{"key":"8096_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K et al (2016) International clinimetric evaluation of the MG-Qol15, resulting in slight revision and subsequent validation of the MG-Qol15r. Muscle Nerve 54:1015\u20131022","journal-title":"Muscle Nerve"},{"key":"8096_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to Lipoprotein-Related protein 4 in patients with double-seronegative myasthenia Gravis. Arch Neurol 69:445\u2013451","journal-title":"Arch Neurol"},{"issue":"6","key":"8096_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.2747","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia Gravis clinical research and care. Muscle Nerve 65(6):630\u2013639. https:\/\/doi.org\/10.1002\/mus.2747","journal-title":"Muscle Nerve"},{"issue":"7","key":"8096_CR18","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP, O\u2019Brien F, Howard JF, REGAIN study group (2020) Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia Gravis treated with Eculizumab. J Neurol 267(7):1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y","journal-title":"J Neurol"},{"issue":"2","key":"8096_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R (2024) Myastenia Gravis: the changing treatment landscape in the era of molecular therapy. Nat Rev Neurol 20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"key":"8096_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of Efgartigimod in patients with generalized myasthenia Gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536","journal-title":"Lancet Neurol"},{"key":"8096_CR21","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Bril V, Vu T et al (2024) Long-term safety, tolerability, and efficacy of Efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia Gravis. Front Neurol 14:1284444. https:\/\/doi.org\/10.3389\/fneur.2023.1284444","journal-title":"Front Neurol"},{"key":"8096_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI106279","volume":"49","author":"A Morell","year":"1970","unstructured":"Morell A, Terry WD, Waldamann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49:673\u2013680","journal-title":"J Clin Invest"},{"key":"8096_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10072-023-07122-y","volume":"45","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C (2024) Efgartigimod improves triple-negative myasthenia Gravis. Neurol Sci 45:1307\u20131309. https:\/\/doi.org\/10.1007\/s10072-023-07122-y","journal-title":"Neurol Sci"},{"issue":"4","key":"8096_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mus.28042","volume":"69","author":"A Mehrabyan","year":"2024","unstructured":"Mehrabyan A, Traub RE (2024) Retrospective review of patients with myasthenia Gravis switched from plasma exchange therapy to Efgartigimod treatment. Muscle Nerve 69(4):467\u2013471. https:\/\/doi.org\/10.1002\/mus.28042Epub 2024 Jan 29","journal-title":"Muscle Nerve"},{"key":"8096_CR25","doi-asserted-by":"publisher","unstructured":"Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K (2024) Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord 39:37\u201341. https:\/\/doi.org\/10.1016\/j.nmd.2024.04.005. Epub 2024 Apr 23. PMID: 38772072","DOI":"10.1016\/j.nmd.2024.04.005"},{"issue":"3","key":"8096_CR26","doi-asserted-by":"publisher","first-page":"e200276","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y et al (2024) Therapeutic responses to Efgartigimod for generalized myasthenia Gravis in Japan. Neurol Clin Pract 14(3):e200276. https:\/\/doi.org\/10.1212\/CPJ.0000000000200276","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"8096_CR27","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W et al (2024) Chinese myasthenia Gravis collaborating group (CMGCG). Epub Efgartigimod for generalized myasthenia Gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol 11(8):2212\u20132221. https:\/\/doi.org\/10.1002\/acn3.52142Epub 2024 Jul 7. PMID: 389731092024 Mar 25. PMID: 38544885","journal-title":"Ann Clin Transl Neurol"},{"key":"8096_CR28","doi-asserted-by":"publisher","unstructured":"Zhu G, Ma Y, Zhou H et al (2024) Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. Front Immunol 15:1401972. https:\/\/doi.org\/10.3389\/fimmu.2024.1401972. eCollection 2024. PMID: 38911858","DOI":"10.3389\/fimmu.2024.1401972"},{"key":"8096_CR29","doi-asserted-by":"publisher","unstructured":"Song J, Wang H, Huan X et al (2024) Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol 15:1418503. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503. eCollection 2024. PMID: 39136012","DOI":"10.3389\/fimmu.2024.1418503"},{"key":"8096_CR30","doi-asserted-by":"publisher","unstructured":"Pane C, Di Stefano V, Cuomo N et al (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. Jul 30. https:\/\/doi.org\/10.1007\/s00415-024-12588-7. Online ahead of print. PMID: 39080054","DOI":"10.1007\/s00415-024-12588-7"},{"key":"8096_CR31","doi-asserted-by":"publisher","unstructured":"Tanaka K, Yoshikawa M, Inoue Y et al (2024) Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibodies. Intern Med. Aug 8. https:\/\/doi.org\/10.2169\/internalmedicine.3726-24. Online ahead of print. PMID: 3911189","DOI":"10.2169\/internalmedicine.3726-24"},{"issue":"6","key":"8096_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/biomedicines12061214","volume":"12","author":"S Konno","year":"2024","unstructured":"Konno S, Uchi T, Kihara H, Sugimoto H (2024) Real-World case series of Efgartigimod for Japanese generalized myasthenia Gravis: Well-Tailored treatment cycle intervals contribute to sustained symptom control. Biomedicines 12(6):1214. https:\/\/doi.org\/10.3390\/biomedicines12061214","journal-title":"Biomedicines"},{"issue":"1","key":"8096_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S et al (2024) Single institution experience with Efgartigimod in patients with myasthenia Gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve 69(1):87\u201392. https:\/\/doi.org\/10.1002\/mus.28003","journal-title":"Muscle Nerve"},{"key":"8096_CR34","doi-asserted-by":"publisher","unstructured":"Habib AA, Sacconi S, Antonini G et al Efficacy and safety of Rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia Gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III mycaring study. Ther Adv Neurol Disord 2024 Sep 12:1717562864241273036. https:\/\/doi.org\/10.1177\/17562864241273036","DOI":"10.1177\/17562864241273036"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08096-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:45:39Z","timestamp":1749530739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08096-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["8096"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08096-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the local hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"C. Antozzi received funding for travel, meeting attendance and advisory board participation from Alexion, Momenta, Sanofi, Janssen, argenx and UCB. F. Vanoli received funding for travel, meeting attendance and consulting by Alexion Pharmaceuticals, UCB Pharma and Argenx. S. Bonanno received funding for travel, meeting attendance and advisory board participation from Sanofi Genzyme, Biogen, Alexion and Roche. R. Frangiamore received funding for travel, consulting, meeting attendance and advisory board participation by argenx, UCB, Alexion, Biogen, Sanofi Genzyme. L. Maggi received funding for travel, meeting attendance, honoraria for speaking and advisory board participation from Sanofi Genzyme, Roche, Biogen, Amicus Therapeutics, Alexion, UCB, argenx, Janssen, Lupin. R. Mantegazza received funding for travel, meeting attendance and advisory board participation from Alexion, argenx, Biomarin, Catalyst, Sanofy Genzyme, Regeneron and UCB. E. Rinaldi, F. Andreetta, E. Ciusani and E. Giacopuzzi have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}